FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 T-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC.